Replies to post #403915 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

While there have been some promising reports emerging from the clinical trials of the two treatments hitting the market in 2023 that target the progression of Alzheimer's—Eisai/Biogen's Lecanemab and Eli Lilly's Donanemab—how well these therapies will work in the broader population remain to be seen. If neither of those therapies prove to be broadly effective—and history tells us that the odds are against them—the outlook for a transformative pharmacological intervention in memory care looks unlikely.


Only Anavex's Anavex 2-73 drug is given a better than 50% chance of making it to market in that timespan, so while it is certainly possible that a product could emerge from the life sciences that would reshape the memory care landscape, it appears unlikely that this will be the case in the near to mid-term.

https://www.advisory.com/blog/2023/01/memory-care

https://investorshub.advfn.com/secure/post_reply.aspx?message_id=171249289

https://www.advisory.com/blog/2023/01/memory-care